CLINICAL TRIALS PROFILE FOR AFATINIB DIMALEATE
✉ Email this page to a colleague
All Clinical Trials for AFATINIB DIMALEATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02122172 ↗ | Afatinib in Advanced Refractory Urothelial Cancer | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2013-10-30 | This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die. |
| NCT02122172 ↗ | Afatinib in Advanced Refractory Urothelial Cancer | Recruiting | University of Chicago | Phase 2 | 2013-10-30 | This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die. |
| NCT02131259 ↗ | Long-term Observation PMS for Afatinib | Completed | Boehringer Ingelheim | 2014-05-07 | In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data for reexamination. Reexamination period is defined by J-PAL. Eight years after approval of a new substance, results of PMS need to be submitted as a part of reexamination dossier to the Japanese regulatory authority, the Ministry of Health, Labour and Welfare (MHLW). | |
| NCT02285361 ↗ | GIOTRIF rPMS in Korean Patients With NSCLC | Completed | Boehringer Ingelheim | 2014-10-31 | To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) | |
| NCT02364609 ↗ | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | Completed | National Cancer Institute (NCI) | Phase 1 | 2015-09-30 | This phase I/Ib trial studies the side effects and best dose of pembrolizumab when given together with afatinib dimaleate in treating patients with non-small cell lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment, or has come back and does not respond to erlotinib hydrochloride. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and afatinib dimaleate together may be an effective treatment for non-small cell lung cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AFATINIB DIMALEATE
Condition Name
Clinical Trial Locations for AFATINIB DIMALEATE
Trials by Country
Clinical Trial Progress for AFATINIB DIMALEATE
Clinical Trial Phase
Clinical Trial Sponsors for AFATINIB DIMALEATE
Sponsor Name
